Form 4: Surmodics CEO Gary Maharaj Exercises Stock Options and Sells Shares
SEC Form 4 Filing
Surmodics CEO Gary Maharaj exercised stock options and sold shares on August 21, 2024, according to a recent SEC filing.
Summary
- Gary R. Maharaj, President & CEO of Surmodics Inc., executed transactions involving the company's stock on August 21, 2024.
- Maharaj exercised employee stock options to acquire 61,017 shares of common stock at a price of $33.20 per share.
- Simultaneously, Maharaj disposed of 50,569 shares at a price of $40.06 per share to cover tax obligations.
- Following these transactions, Maharaj directly owns 202,582 shares of Surmodics Inc.
- The filing also notes that Maharaj acquired 464 shares through the Employee Stock Purchase Plan for the phase ending on February 29, 2024.
Sentiment
Score: 5
Explanation: Neutral sentiment. The transactions are routine and don't necessarily indicate a strong positive or negative outlook.
Positives
- The exercise of stock options could be seen as a positive signal, indicating the CEO's confidence in the company's future performance.
Negatives
- The sale of shares, even if to cover tax obligations, could be interpreted negatively by some investors.
Risks
- Executive stock transactions can sometimes create uncertainty in the market, depending on the scale and context of the transactions.
Industry Context
Executive stock transactions are a common occurrence in publicly traded companies. They are often scrutinized by investors for insights into management's perspective on the company's valuation and future prospects. The sale of shares to cover tax obligations is a typical practice.
Comparison to Industry Standards
- Executive compensation packages, including stock options, are standard practice in publicly traded companies like Surmodics.
- The exercise of stock options and subsequent sale of shares for tax purposes is a common financial planning strategy among executives at companies such as Medtronic, Boston Scientific, and Abbott.
Stakeholder Impact
- The transactions may have a minor impact on shareholders, depending on how they interpret the CEO's actions.
Key Dates
| Date | Description |
|---|---|
| 02/29/2024 | End date of Employee Stock Purchase Plan phase during which 464 shares were acquired. |
| 08/21/2024 | Date of stock option exercise and share sale transactions. |
| 08/23/2024 | Date of signature on the SEC Form 4 filing. |
| 11/28/2024 | Expiration date of the employee stock options. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.